Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of MK-3102 (omarigliptin) in younger adults with type 2 diabetes mellitus and inadequate glycemic control
2012-004303-12Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MK-3102 (omarigliptin) with Placebo (2 arms). Primary endpoint: Change from baseline in A1C. Started Aug 2014; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-004303-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004303-12.